Alessia Silvestrin

Dr. Alessia Silvestrin

University of Campania "Luigi Vanvitelli", Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Mario RomeoMario Romeo
Mario Romeo
ASAlessia Silvestrin
Alessia Silvestrin
Giusy SeneseGiusy Senese
Giusy Senese
FNFiammetta Di Nardo
Fiammetta Di Nardo
CNCarmine Napolitano
Carmine Napolitano
AFAlessandro Federico
Alessandro Federico
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic hepatopathy and a leading precursor of hepatocellular carcinoma (HCC) worldwide. Initially attributed to insulin resistance (IR)-driven metabolic imbalance, recent insights highlight a multifactorial pathogenesis involving oxidative stress (OS), chronic inflammation, and immune dysregulation. The hepatic accumulation of free fatty acids (FFAs) initiates mitochondrial dysfunction and excessive reactive oxygen species (ROS) production, culminating in lipotoxic intermediates and mitochondrial DNA damage. These damage-associated molecular patterns (DAMPs), together with gut-derived pathogen-associated molecular patterns (PAMPs), activate innate immune cells and amplify cytokine-mediated inflammation. Kupffer cell activation further exacerbates OS, while ROS-induced transcriptional pathways perpetuate inflammatory gene expression. Traditional immunity refers to the well-established dichotomy of innate and adaptive immune responses, where innate immunity provides immediate but non-specific defense, and adaptive immunity offers long-lasting, antigen-specific protection. However, a paradigm shift has occurred with the recognition of trained immunity (TI)—an adaptive-like memory response within innate immune cells that enables enhanced responses upon re-exposure to stimuli. Following non-specific antigenic stimulation, TI induces durable epigenetic and metabolic reprogramming, leading to heightened inflammatory responses and altered functional phenotypes. These rewired cells acquire the capacity to produce lipid mediators, cytokines, and matrix-modifying enzymes, reinforcing hepatic inflammation and fibrogenesis. In this context, the concept of immunometabolism has gained prominence, linking metabolic rewiring with immune dysfunction. This literature review provides an up-to-date synthesis of emerging evidence on immunometabolism and trained immunity as pathogenic drivers in MASLD. We discuss their roles in the transition from hepatic steatosis to steatohepatitis, fibrosis, and cirrhosis, and explore their contribution to the initiation and progression of MASLD-related HCC. Understanding these processes may reveal novel immunometabolic targets for therapeutic intervention.

Verified
Journal Article
Open access
PDF file
MDMarcello Dallio
Marcello Dallio
Mario RomeoMario Romeo
Mario Romeo
FNFiammetta Di Nardo
Fiammetta Di Nardo
PVPaolo Vaia
Paolo Vaia
CNCarmine Napolitano
Carmine Napolitano
AFAlessandro Federico
Alessandro Federico
Alpha-Glutathione-S-transferase (alphaGST) is a liver enzyme whose serum levels increase with the worsening of fibrosis in alcoholic and viral chronic hepatitis. Its usefulness in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) remains unexplored. From January 2016 to December 2017, 200 patients with MASLD and 30 controls were enrolled. AlphaGST serum levels were measured. Variables related to advanced fibrosis (AF) were selected via Principal Component Analysis (PCA), and the best cut-off (BCO) was estimated using ROC analysis. Liver stiffness measurement (LSM), NAFLD fibrosis (NFS), Fibrosis-4 (FIB-4), and BMI-AST/ALT Ratio-Diabetes (BARD) scores were determined. The first acute cardiovascular events (ACE) in ACE-naïve subjects were recorded over five years. A validation cohort of 60 MASLD patients was enrolled from January 2018 to May 2019 and followed for five years. AlphaGST levels increased with fibrosis stage (p < 0.0001) in both cohorts, showing high accuracy in predicting AF (TrC: AUC 0.89, VlC: AUC 0.89). PCA-selected variables were HbA1c, HDL, and alphaGST, forming the “FLAME” model. FLAME showed superior predictive performance for AF and ACEs compared to other models and scores. FLAME represents a novel tool that accurately predicts AF and ACEs in MASLD.

31 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MDMarcello Dallio
Marcello Dallio
Mario RomeoMario Romeo
Mario Romeo
FNFiammetta Di Nardo
Fiammetta Di Nardo
Giusy SeneseGiusy Senese
Giusy Senese
ASAlessia Silvestrin
Alessia Silvestrin
AFAlessandro Federico
Alessandro Federico
Background/Objectives: Fonte Essenziale®, a mineral water rich in bicarbonate, sulfate, calcium, and magnesium, has shown potential in modulating the gut–liver axis and microbiota in hepatic steatosis. However, its long-term effects on intestinal permeability (IP), systemic inflammation (SI), and oxidative stress—key factors in Metabolic dysfunction-associated steatotic liver disease (MASLD)—remain unexplored. Methods: Eighty-seven MASLD patients were randomized into two groups: group A received Fonte Essenziale® (400 mL/day, fasting) plus a controlled nutritional regimen for 12 months, followed by a 6-month water washout; group B followed only the controlled nutritional regimen. IP markers, SI (IL-1β, IL-6, TNF-α), oxidative stress (dROMs/BAP), and clinical data (including Controlled Attenuation Parameter—CAP) were assessed at baseline (T0), 12 months (T12), and post-washout (T18). Baseline increased IP (in-IP) was defined by fecal zonulin > 110 ng/mL and serum LBPp > 10 µg/mL; improvement (im-IP) required normalization of both. A ≥30% CAP reduction indicated steatosis improvement. Results: Thirty-eight patients in group A and thirty-nine in group B completed the study. At T12, group A showed significant reductions in fecal zonulin (p: 0.0163) and serum LBPp (p < 0.0001), with increased occludin and claudin 1 (all p < 0.0001). Im-IP prevalence was higher in group A (p: 0.0037). Group A also showed significant reductions in IL-1β, TNF-α, IL-6, LPS, and dROM/BAP (all p < 0.05), especially among those with im-IP. CAP, insulin, and HDL levels improved significantly (all p < 0.0001). Multivariate analysis confirmed water intake (aOR: 2.185, p: 0.001) and im-IP achievement (aHR: 1.267, p: 0.021) as predictors of steatosis improvement. Benefits persisted at T18. Conclusions: Prolonged Fonte Essenziale® intake improved hepatic steatosis and MASLD outcomes by modulating IP, SI, and oxidative stress. This trial has been registered on clinicaltrials.gov (NCT07211113).

12 November 2025 in Livers
Verified
Journal Article
Open access
PDF file
MDMarcello Dallio
Marcello Dallio
Mario RomeoMario Romeo
Mario Romeo
FNFiammetta Di Nardo
Fiammetta Di Nardo
CNCarmine Napolitano
Carmine Napolitano
PVPaolo Vaia
Paolo Vaia
AFAlessandro Federico
Alessandro Federico
Background/Objectives: In the present study, the Metabolic dysfunction-associated fatty liver disease (MAFLD) and Metabolic dysfunction-associated steatotic liver disease (MASLD) diagnostic criteria were applied to evaluate the relative performance in predicting short-term advanced fibrosis (AF) progression (AFpr) and hepatocellular carcinoma (HCC), as well as an ancillary outcome, i.e., the occurrence of acute cardiovascular events (ACEs) in steatotic liver disease (SLD) patients. Methods: We retrospectively analyzed the data stored in the University Hospital (UH)’s Official Health Documents Digitization Archive of 931 SLD patients, with a follow-up of 3 years. Based on the Body Mass Index (BMI), patients were subdivided into lean “L” (BMI < 25 kg/m2) (n = 134) and not-lean “NL” (n = 797), and, subsequently, into NL-MASLD (n = 206), NL-MASLD/MAFLD (n = 481), NL-MAFLD (n = 110), L-MASLD (n = 39), L-MASLD/MAFLD (n = 68), and L-MAFLD (n = 27). All study outcomes (AFpr, HCC, and ACE) were primarily evaluated in NL-SLD and by conducting a sub-analysis of L-SLD individuals. Results: MASLD and MAFLD criteria similarly estimated [p = 0.076] the overall 3-year risk of AF progression in NL-SLD. In the L-SLD sub-analysis, MAFLD criteria better estimated the overall 3-year risk of AF progression [p = 0.006]. Multivariate competing risk analysis (adjusted for sex, age, diabetes, steatosis, and fibrosis severity) revealed diabetes [adjusted Hazard Ratio (aHR) = 2.113, p = 0.001], high-sensitivity C-reactive protein (aHR = 1.441; p = 0.02), and Homeostatic Model Assessment for Insulin Resistance (aHR = 1.228; p = 0.03) as being associated with AF progression in L-MAFLD. Compared to MAFLD, MASLD diagnostic criteria similarly estimated the 3-year risk of HCC occurrence both in NL [HR = 1.104, C.I. 95%: 0.824–1.593, p = 0.741] and L [HR = 1.260, C.I. 95%: 0.768–2.104, p = 0.701] patients. Finally, no significant differences were reported between the MAFLD or MASLD criteria for ACE risk occurrence in all study groups. Conclusions: The MAFLD criteria better estimate the AF progression risk, limited to L-SLD patients.

2 May 2025 in Livers
Verified
Journal Article
Open access
PDF file
Mario RomeoMario Romeo
Mario Romeo
MDMarcello Dallio
Marcello Dallio
FNFiammetta Di Nardo
Fiammetta Di Nardo
GMGiuseppina Martinelli
Giuseppina Martinelli
CBClaudio Basile
Claudio Basile
AFAlessandro Federico
Alessandro Federico
The term “plastics” is an umbrella term generally referring to any material containing a high level of polymer content as an essential ingredient. Micro(nano)plastics (MNPs) are derived from the degradation of plastics, representing exogenous substances whose exposure can potentially interfere with different physiological processes. In this scenario, even considering the relative paramount detoxification role, the liver emerges as a key active organ in the relationship between plastic exposure and human disease. In industrialized countries, where plastics constitute largely diffused components of objects routinely adopted in daily/social life, including food packaging, Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) represents the predominant hepatopathy and is progressively becoming the leading cause of cirrhosis and liver cancer, with an incompletely elucidated multifactorial pathogenesis. Notably, oral exposure to MNPs has been revealed to impact the gut–liver axis by influencing gut microbiota composition, gastrointestinal absorption, and, ultimately, determining hepatic accumulation. At the hepatic level, MNPs can contribute to the onset and worsening of steatosis by inducing metabolic dysfunction and inflammation. Plastics can also serve as vectors for different potentially toxic additives, with specific MNPs constituting a persistent source of release of bisphenol A (BPA), a well-recognized exogenous etiological factor contributing to MASLD genesis and worsening. Recently, exposure to MNPs and additives has demonstrated significant impacts on the immune system, oxidative stress, and metabolism. In particular, polystyrene-derived MNPs impair the mechanisms regulating hepatic lipid metabolism, simultaneously acting as antigens abnormally triggering the innate immune response. At the same time, environmental BPA exposure has been revealed to trigger trained immunity-related pathways, configuring novel pathogenetic drivers potentially promoting the progression of MASLD. The present review, after rapidly overviewing the main sources and toxicological properties of MNPs and related additives, explores plastic-related exposure’s potential implications in the genesis and progression of hepatic steatosis, highlighting the urgent need for further clarification of relative pathogenetic mechanisms.

18 September 2025 in Archives of Medical Research
Verified
Journal Article
Open access
MDMarcello Dallio
Marcello Dallio
Mario RomeoMario Romeo
Mario Romeo
ACAnnachiara Coppola
Annachiara Coppola
GMGiuseppina Martinelli
Giuseppina Martinelli
CBClaudio Basile
Claudio Basile
AFAlessandro Federico
Alessandro Federico
Phase angle (PA), a bioelectrical impedance analysis (BIA)-assessable marker of sarcopenia, can accurately predict hospitalizations in advanced chronic liver disease (ACLD). PA has never been specifically investigated in metabolic dysfunction-associated steatotic liver disease (MASLD). Sarcopenia is commonly observed in patients with MASLD, whereas individuals with compensated ACLD (cACLD)-MASLD progress more rapidly to decompensated ACLD (dACLD). To evaluate the PA values across the different stages of liver disease progression in MASLD, and to estimate the accuracy of the novel PA/C-reactive-protein (CRP) index (PAC-I) in predicting 3 month further liver-related events (LREs) and hospitalizations in MASLD-dACLD. Patients with MASLD were consecutively enrolled and stratified according to liver stiffness measurement (LSM) and eventual previous LREs in ≤F3 fibrosis (AF), cACLD, and dACLD. At baseline, anthropobiochemical, nutritional, and clinical data were collected. Patients with MASLD-dACLD were followed up, and further LRE-determining hospitalizations within the subsequent three months were recorded. In patients with MASLD, PA values were inversely correlated with LSM, and progressively decreased according to the worsening of liver disease (cACLD vs. dACLD, p <0.0001). In patients with dACLD, PA inversely correlated with CRP levels. PAC-I showed greater accuracy and superiority compared to PA alone in predicting the occurrence of further LREs within three months (PAC-I <2.35: optimal cut-off). Consistently, patients with dACLD with PAC-I <2.35 presented a higher risk of further LREs. In MASLD, PA correlates with disease progression status. PAC-I represents a useful noninvasive tool in predicting short-term liver-related hospitalizations in dACLD.